| Literature DB >> 33008333 |
Raphael Awah Abong1,2, Glory N Amambo1,2, Patrick W Chounna Ndongmo1,2, Abdel Jelil Njouendou1,3, Manuel Ritter4, Amuam Andrew Beng1,2, Mathias Eyong Esum1,2, Kebede Deribe5,6, Jerome Fru-Cho1,2, Fanny F Fombad1,2, Theobald Mue Nji2,7, Peter Ivo Enyong1,2, Catherine B Poole8, Kenneth Pfarr4,9, Achim Hoerauf4,9, Clotilde K S Carlow8, Samuel Wanji10,11.
Abstract
BACKGROUND: Ivermectin is an excellent microfilaricide against Onchocerca volvulus. However, in some regions, long term use of ivermectin has resulted in sub-optimal responses to the treatment. More data to properly document the phenomenon in various contexts of ivermectin mass drug administration (IVM-MDA) is needed. Also, there is a need to accurately monitor a possible repopulation of skin by microfilariae following treatment. Skin snip microscopy is known to have a low sensitivity in individuals with light infections, which can be the case following treatment. This study was designed with two complementary objectives: (i) to assess the susceptibility of O. volvulus microfilariae to ivermectin in two areas undergoing IVM-MDA for different lengths of time, and (ii) to document the repopulation of skin by the O. volvulus microfilariae following treatment, using 3 independent diagnostic techniques.Entities:
Keywords: LAMP; Microfilaricides; Microfilaridemia; Microscopy; Monitoring; O. volvulus; Real-time PCR; Susceptibility
Mesh:
Substances:
Year: 2020 PMID: 33008333 PMCID: PMC7530974 DOI: 10.1186/s12879-020-05444-2
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Overview of the study area including Bafia and Melong Health Districts and study communities. This map was created using ArcGIS (ArcMap v10.5.1) software
Fig. 2Overview of the study design
Screened participants positive for O. volvulus Mf in the Bafia HD
| Variables | Study populations | Number examined | Number positive | Percentage (%) | |
|---|---|---|---|---|---|
| Male | 229 | 73 | 31.9 | 0.018 | |
| Female | 159 | 32 | 20.1 | ||
| Children (5–19 years) | 76 | 10 | 13.2 | 0.007 | |
| Adults (≥20 years) | 312 | 95 | 30.4 | ||
| Balamba 1 | 28 | 7 | 25.0 | 0.001 | |
| Balamba 2 | 57 | 5 | 8.8 | ||
| Biamo | 68 | 23 | 33.8 | ||
| Boalondo/Botatango | 53 | 24 | 45.3 | ||
| Lable/Nyamsong | 88 | 12 | 13.6 | ||
| Ngomo/Biatsota | 94 | 34 | 36.2 | ||
Screened participants positive for O. volvulus Mf in the Melong HD
| Variables | Study populations | Number examined | Number positive | Percentage (%) | |
|---|---|---|---|---|---|
| Male | 283 | 44 | 15.5 | 0.005 | |
| Female | 316 | 26 | 8.2 | ||
| Children (5–19 years) | 132 | 15 | 11.4 | 0.896 | |
| Adults (≥20 years) ( | 467 | 55 | 11.8 | ||
| Mounko | 60 | 4 | 6.7 | 0.002 | |
| Manjibo | 51 | 12 | 23.5 | ||
| Singa/Mbie/Barembeng2/Longze | 104 | 10 | 9.6 | ||
| Ndoumbot/Ntangtom | 55 | 14 | 25.5 | ||
| Nkoniakoniama/Nkonianke/Nkoniambot | 87 | 7 | 8.0 | ||
| Ndom-Bakem | 79 | 10 | 12.7 | ||
| Barembeng1 | 101 | 8 | 7.9 | ||
| Mpaka | 62 | 5 | 8.1 | ||
Fig. 3Microfilaridemia clearance and repopulation dynamics at 30, 60 and 90 days post direct observed IVM treatment in the Bafia and Melong HDs: a Proportion of microfilaridemia positivity. b Geometric mean microfilarial density per skin snip (GMMfD/ss). C) Percent reduction in GMMfD/ss
Microfilaridemia detection rates by microscopy, actin-qPCR and O-150 LAMP at day 30, 60 and 180 post IVM treatment in Bafia HD
| Time point after treatment (days) | Number of consented eligible participants | Number of samples collected | Proportion positive for microscopy n(%) | Proportion positive for real-time PCR n(%) | Proportion positive for O-150 LAMP n(%) |
|---|---|---|---|---|---|
| 51 | 51 | 11 (21.6%) | 12 (23.5%) | 15 (29.4%) | |
| 51 | 51 | 12 (23.5%) | 16 (31.4%) | 19 (37.3%) | |
| 51 | 48 | 22 (45.8%) | 26 (54.2%) | 31 (64.6%) | |
| P = 0.014 | P = 0.005 | P = 0.001 |
n = number of cases detected by each method
Fig. 4O. volvulus microfilaridermia positivity rate at different time points following IVM treatment in the Bafia health district using microscopy, actin-qPCR and O-150 LAMP assays
Microfilaridemia detection rate by microscopy, actin-qPCR and O-150 LAMP at day 30, 60 and 180 post IVM treatment in Melong HD
| Time point after treatment (days) | Number of consented eligible participants | Number of samples collected | Proportion positive for microscopy n(%) | Proportion positive for real-time PCR n(%) | Proportion positive for O-150 LAMP n(%) |
|---|---|---|---|---|---|
| 44 | 29 | 2 (6.9%) | 4 (13.8%) | 7 (24.1%) | |
| 44 | 44 | 9 (20.5%) | 7 (15.9%) | 12 (27.3%) | |
| 44 | 38 | 9 (23.7%) | 9 (23.7%) | 16 (42.1%) | |
| 111 | |||||
n = number of cases detected by each method
Fig. 5O. volvulus microfilaridemia positivity rate at different time points following IVM treatment in Melong HD using microscopy, actin-qPCR and O-150 LAMP assay
Performance characteristics of the three tests in Bafia HD. Summary of sensitivity, specificity, PPV and NPV for microscopy, actin-qPCR and O-150 LAMP at different time points following direct observed treatment of microfilaridermic individuals with ivermectin in Bafia health district
| METHODS | SENSITIVITY | SPECIFICITY | PPV | NPV |
|---|---|---|---|---|
| MICROSCOPY | 89.6 (61.6–99.9) | 99.3 (93.0–100) | 97.6 (76.9–100) | 96.9 (86.2–100) |
| REAL-TIME PCR | 89.6 (64.5–99.6) | 96.8 (87.5–99.9) | 89.6 (62.2–99.7) | 96.8 (87.2–99.9) |
| LAMP ASSAY | 97.6 (78.7–100) | 92.1 (80.6–98.8) | 79.0 (53.2–97.1) | 99.2 (91.9–100) |
| MICROSCOPY | 71.4 (45.8–91.8) | 96.9 (88.0–99.8) | 90.6 (67.0–99.5) | 88.8 (74.8–97.3) |
| REAL-TIME PCR | 97.5 (75.8–100) | 97.0 (86.3–100) | 93.2 (69.3–99.9) | 98.9 (87.8–100) |
| LAMP ASSAY | 97.5 (79.0–100) | 88.7 (75.0–97.6) | 78.6 (54.5–95.7) | 98.8 (89.1–100) |
| MICROSCOPY | 80.6 (62.9–93.1) | 94.8 (81.3–99.6) | 94.9 (80.6–99.6) | 80.8 (61.5–93.4) |
| REAL-TIME PCR | 98.9 (87.3–100) | 98.5 (84.6–100) | 98.8 (86.4–100) | 98.7 (83.4–100) |
| LAMP ASSAY | 99.0 (90.1–100) | 76.6 (56.3–91.6) | 83.4 (66.9–94.3) | 98.6 (85.2–100) |
| MICROSCOPY | 80.7 (68.4–90.2) | 97.4 (93.1–99.5) | 94.5 (85.1–98.9) | 90.3 (83.1–95.2) |
| REAL-TIME PCR | 98.1 (90.0–100) | 97.6 (92.7–99.8) | 95.7 (87.1–99.6) | 99.0 (94.2–100) |
| LAMP ASSAY | 99.4 (93.4–100) | 87.1 (79.4–93.1) | 80.7 (69.6–89.9) | 99.6 (95.8–100) |
Performance characteristics of the three tests in Melong HD. Summary of sensitivity, specificity, PPV and NPV for Microscopy, actin-qPCR and O-150 LAMP at different time points following direct observed treatment of microfilaridermic individuals with ivermectin in Melong Health District
| METHODS | SENSITIVITY | SPECIFICITY | PPV | NPV |
|---|---|---|---|---|
| MICROSCOPY | 45.4 (10.1–91.2) | 99.1 (89.7–100) | 89.6 (29.3–100) | 91.1 (71.0–99.2) |
| REAL-TIME PCR | 87.6 (32.2–100) | 98.7 (87.1–100) | 92.2 (36.2–100) | 98.0 (78.3–100) |
| LAMP ASSAY | 94.2 (52.0–100) | 89.3 (71.5–99.7) | 60.5 (18.4–99.3) | 98.9 (87.4–100) |
| MICROSCOPY | 90.6 (48.3–100) | 94.7 (82.3–100) | 78.9 (35.2–99.9) | 98.0 (82.0–100) |
| REAL-TIME PCR | 38.0 (10.9–80.6) | 99.4 (92.9–100) | 93.1 (43.4–100) | 87.8 (69.8–97.9) |
| LAMP ASSAY | 92.1 (55.3–100) | 89.8 (75.9–99.7) | 66.1 (28.1–99.2) | 98.1 (84.9–100) |
| MICROSCOPY | 88.9 (58.1–99.9) | 96.1 (84.9–99.8) | 87.5 (59.2–99.4) | 96.5 (84.5–100) |
| REAL-TIME PCR | 96.7 (69.9–100) | 98.8 (89.2–100) | 96.2 (66.7–100) | 99.0 (89.4–100) |
| LAMP ASSAY | 97.1 (74.0–100) | 75.3 (58.7–88.5) | 55.0 (30.6–78.2) | 98.9 (87.7–100) |
| MICROSCOPY | 80.2 (57.2–95.0) | 95.9 (89.4–99.2) | 81.5 (56.6–96.4) | 95.7 (87.9–99.0) |
| REAL-TIME PCR | 78.3 (53.3–97.9) | 99.7 (96.5–100) | 98.2 (82.1–100) | 95.4 (87.4–99.7) |
| LAMP ASSAY | 98.5 (84.3–100) | 84.7 (75.6–92.3) | 58.7 (39.1–79.4) | 99.6 (95.4–100) |